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Veno-venous (VV) extracorporeal membrane oxygena-
tion (ECMO) has become an integral part in the rescue 
therapy of severe acute respiratory distress syndrome 
(ARDS) and may be lifesaving in patients with refractory 
hypoxemia [1]. Ventilator-induced lung injury, ventilator-
acquired pneumonia and ventilator-induced diaphragm 
dysfunction are severe side effects of invasive ventila-
tion and may contribute to the complex pathophysiology 
of multi-organ failure and death in ARDS [2]. The use 
of ECMO in patients who are awake and spontaneously 
breathing (termed awake ECMO) might avoid side effects 
and complications associated with sedation, intuba-
tion and invasive mechanical ventilation [3]. Our group 
reported the first successful use of awake ECMO in six 
ARDS patients several years ago [4]. We then concluded 
that the concept of an awake ECMO strategy as a poten-
tial alternative to intubation deserves further evaluation 
especially in patients with higher mortality following tra-
ditional invasive ventilation and ECMO support.
In immunocompromised patients with ARDS who 
require ECMO support, the 6-month mortality exceeds 
70% with a reported in-hospital mortality of 81% in 
patients following hematopoietic stem cell transplanta-
tion (HSCT) [5]. In immunocompromised patients with 
Pneumocystis jirovecii-associated pneumonia and severe 
ARDS we demonstrated earlier that a primarily awake 
ECMO strategy seems to be a promising strategy [6].
We therefore hypothesized that awake ECMO support 
to avoid invasive ventilation in selected immunocompro-
mised patients might yield improved outcomes. Here, 
we present a comprehensive summary of 18 immuno-
compromised patients who received awake ECMO sup-
port for management of ARDS at our institution between 
09/2012 and 09/2020.
The patient characteristics are shown in Table  1. At 
inclusion, the majority of patients had isolated lung fail-
ure indicated by rather low rates of low-dose vasopres-
sor support (28%) and renal replacement therapy (6%) 
as well as physiological serum lactate concentrations. 
Median (Interquartile Range (IQR)) oxygenation indices 
at ECMO initiation were 72 (65–82) mmHg with normal 
values for pH and  pCO2 despite maximal respiratory sup-
port by noninvasive ventilation (NIV). ECMO was initi-
ated after a median of 1 (1–3) days following initial ICU 
admission and was carried out for 11 (9–18) days.
Eleven patients (61%) required secondary intubation 
after a median of 4 (2–6) days. The most common cause 
for secondary intubation was agitation (6/11, 55%) stress-
ing the critical role for delirium preventive strategies in 
these patients. The majority (4/6) of patients with agita-
tion as primary cause for failing awake ECMO support 
developed agitation without any prior respiratory or 
circulatory deterioration. The choice of anxiolytic medi-
cation showed a trend toward a more frequent use of 
benzodiazepines in patients with agitation compared to 
all other patients (6/6 vs. 4/12), while low-dose morphine 
was used less frequently (2/6 vs. 7/12).
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28-day-, in hospital- and 6-month mortality rates were 
44% (8/18), 50% (9/18) and 50%, respectively. In-hospital 
mortality was 29% (2/7) in solid organ transplantation 
patients and 50% (3/6) in hemopoietic stem cell trans-
plantation patients. In-hospital mortality was 73% in 
patients who required secondary intubation and 14% in 
patients who did not require intubation while on ECMO 
support (p = 0.023, Hazard Ratio: 0.133 (0.058–0.789)).
Table 1 Demographic and clinical characteristics at initiation of 
awake ECMO support
Characteristic at inclusion Median (IQR)/no (%)
Number of patients 18
Age—years 54 (36–60)
Sex—no (%)
 Male 11 (61.1)
 Female 7 (38.9)
BMI—kg/m2 24.5 (21.3–27.1)
Adipositas (BMI > 30 kg/m2)—no (%) 2 (11.1)
Cause of immunosupression—no (%)
 Solid organ transplant 7 (38.9)
 HSCT 6 (33.3)
 AIDS 2 (11.1)
 Rheumatological disease 3 (16.7)
Pathogen—no (%)
 Gram + 2 (11.1)
 Gram− 3 (16.7)
 CMV 1 (5.6)
 Fungal 2 (11.1)
 PcP 8 (44.4)
 Non-identified 5 (27.8)
Comorbidities—no (%)
 COPD 3 (16.7)
 Cystic fibrosis 1 (5.6)
 Pulmonary fibrosis 6 (33.3)
 Pulmonary hypertension 1 (5.6)
 Arterial hypertension 5 (27.8)
 Congestive heart failure 1 (5.6)
 Diabetes mellitus 3 (16.7)
 Chronic kidney disease 5 (27.8)
Ventilation support—no (%)
 HFNC 1 (5.6)
 NIV 17 (94.4)
Respiratory parameters
  FiO2 1 (1–1)
 PEEP—cmH2O 7 (5–8)
 Breaths per minute 32 (29–38)
 Tidal volume—ml 593 (476–786)
 Minute ventilation—l/min 21.3 (13.8–24.4)
 Peak—cmH2O 17 (14–19)
  PaO2—mmHg 65 (58–82)
  PaO2/FiO2—mmHg 72 (65–82)
  PaCO2—mmHg 40 (35–59)
 pH 7.36 (7.3–7.44)
 Lactate—mmol/l 1.5 (1.2–1.9)
 Vasopressor—no (%) 5 (27.8)
 Norepinephrine dose—μg/kg/min 0 (0–0.068)
 Inotropic—no (%) 0 (0)
 Renal replacement therapy—no (%) 1 (5.6)
 SOFA-score (points) 7 (4–8)
Organ dysfunction—no (%)
Description of the patient cohort (n = 18) that received awake ECMO support. 
All immunocompromised patients with severe ARDS were non-systematically 
screened by two ECMO experienced ICU attending intensivists for the possibility 
of an awake ECMO strategy following inclusion and exclusion criteria that have 
been previously defined by our group as part of the study describing first use of 
awake ECMO in ARDS patients (4) (NCT01669863). In general, the exclusion criteria 
stressed the absence of septic or cardiogenic shock and multi-organ failure
Given are demographic and clinical characteristics at the time of ECMO 
initiation. Values are presented as median (25–75% interquartile range) or if 
categorical as numbers and percentage
BMI, Body Mass Index; HSCT, Hematopoietic Stem Cell Transplantation; 
AIDS, Acquired Immuno Deficiency Syndrome; CMV, Cytomegalovirus; PcP, 
Pneumocystis carinii Pneumonia; COPD, Chronic Obstructive Pulmonary Disease; 
HFNC, High Flow Nasula Cannula; NIV, Non Invasive Ventilation;  FiO2, Fraction on 
inspired oxygen; PEEP, Positive End Expiratory Pressure; rpm, rounds per minute; 
Ppeak, Peak Pressure; SOFA, Sequential Organ Failure Assessment Score; GCS, 
Glasgow Coma Score; CRP, C Reactive Protein; PCT, Procalcitonin
Table 1 (continued)
Characteristic at inclusion Median (IQR)/no (%)
 Respiratory  (PaO2/FiO2 < 300) 18 (100)
 Coagulation (thrombocytes < 100) 5 (27.8)
 Liver (bilirubin > 33 μmol/l) 2 (11.1)
 Cardiovascular (dobutamine or noradrenaline) 5 (27.8)
 Neurological (GCS < 13) 0 (0)
 Renal (creatinine > 170 μmol/l) 3 (16.7)
Multi-organ dysfunction—no (%)
 Two 11 (61.1)
 Three 1 (5.6)
 Four 1 (5.6)
 Five 0 (0)




24 h diuresis—ml 1230 (360–2165)
ECMO settings (directly after cannulation)
 Veno-venous 18 (100)
Cannulation (inflow–outflow)
 Femoral-jugular 16 (88.8)
 Femoral–femoral 1 (5.6)
 Femoral-subclavia 1 (5.6)
Pump speed—rpm 3410 (3030–3671)
Blood flow—l/min 3.6 (3.3–4)
FiO2 100 (100–100)
Sweep gas flow—l/min 3.5 (2–4.1)
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An exploratory analysis suggested several factor asso-
ciated with later failure of an awake ECMO concept 
(Table 2).
Although this study, to the best of our knowledge, 
represents the largest experience with awake ECMO in 
ARDS patients, conclusions are still limited by its small 
sample size and the uncontrolled nature. Despite these 
limitations, our findings support the notion that an awake 
ECMO strategy might be a viable treatment option for 
immunocompromised patients with severe ARDS, espe-
cially in those patients without overt multi-organ failure. 
Further studies are required to determine the possible 
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Table 2 Predictors for failure of the awake ECMO concept
Description of parameters that were associated with the necessity of later secondary intubation. Factors associated with later failure of an awake ECMO concept were 
more prominent use of benzodiazepines during awake ECMO support, higher peak pressures applied in noninvasive ventilation and hypercapnia directly before 
ECMO insertion as well as longer ECMO support. Values are presented as median (25–75% interquartile range) or if categorical as numbers and percentage
CI, Confidence Interval; NIV, Noninvasive Ventilation; Ppeak, Peak Pressure
Characteristic Secondary intubation Logistic regression
No Yes p OR 95%-CI p
Benzodiazepine use during ECMO support—no (%) 2/7 (28.6) 8/11 (72.7) 0.066 6.7 0.8–55 0.078
Ppeak (NIV) before ECMO initiation—cmH2O 15 (11–16) 19 (17–22) 0.014 1.6 1–2.6 0.05
pCO2 before ECMO initiation—mmHg 37 (35–43) 50 (34–76) 0.06 1.1 1–1.2 0.163
ECMO support duration—days 9 (8–11) 12 (10–28) 0.049 1.2 0.9–1.5 0.173
